Association of Clinical Benign Prostate Hyperplasia with Prostate Cancer Incidence and Mortality Revisited: A Nationwide Cohort Study of 3 009 258 Men

作者：Orsted David D; Bojesen Stig E; Nielsen Sune F; Nordestgaard Borge G^*

来源：European Urology, 2011, 60(4): 691-698.

DOI：10.1016/j.eururo.2011.06.016

• Clinical benign prostate hyperplasia
• Prostate cancer
• Incidence
• Mortality
• Epidemiology

Background: Although benign prostate hyperplasia (BPH) and prostate cancer (PCa) share features such as hormone-dependent growth and response to treatment with antiandrogen therapy, BPH is generally not considered a premalignant lesion.
Objective: To determine whether clinical BPH is associated with an increased risk of PCa incidence and mortality.
Design, setting, and participants: Using designs with individual participant data from five national registries, we studied the entire Danish male population from 1980 through 2006, a total of 3 009 258 Danish men. We collected PCa diagnoses (n = 53 315), information on PCa mortality (n = 25 459), and ascertained clinical BPH (not histologically proven BPH) through hospitalization (n = 187 591) and/or surgery (n = 77 698) from 1980 to 2006 and the use of alpha-adrenergic receptor antagonists (n = 143 365) and/or the use of 5 alpha-reductase inhibitors (5-ARIs) (n = 47 465) from 1995 to 2006.
Measurements: PCa incidence and mortality was assessed for each category of clinical BPH using Kaplan-Meier plots of cumulative incidence and Cox proportional hazard ratios (HRs) adjusted for potential confounders.
Results and limitations: For the entire cohort studies, multivariate-adjusted HRs for PCa incidence were 2.22 (95% confidence interval, 2.13-2.31) in men hospitalized and 3.26 (3.03-3.50) in men operated on for clinical BPH versus general population controls. Corresponding HRs for PCa mortality were 2.00 (1.91-2.08) for hospitalization and 7.85 (7.40-8.32) for surgery. For age-matched cohort studies, corresponding HRs for PCa incidence were 3.04 (2.96-3.13) for hospitalization, 2.60 (2.47-2.73) for surgery, 4.49 (4.33-4.65) for alpha-adrenergic receptor antagonist use, and 2.54 (2.40-2.68) for 5-ARI use. Each category of clinical BPH has limitations, but limitations differ between the categories and therefore are unlikely to explain the results.
Conclusions: In Danish men followed for up to 27 yr, clinical BPH was associated with a two-to three-fold increased risk of PCa incidence and with a two-to eight-fold increased risk of PCa mortality. These data should not be used to infer causality.

• 出版日期2011-10